Results 291 to 300 of about 20,100 (304)

A prospective randomized, controlled trial of eculizumab to prevent ischemia‐reperfusion injury in pediatric kidney transplantation

Pediatric Transplantation, 2018
M M Kaabak, Zhaoqing Pan, Ashesh Mahto
exaly  

Predictors of hemoglobin response to eculizumab therapy in paroxysmal nocturnal hemoglobinuria

European Journal of Haematology, 2013
Robert A Brodsky
exaly  

Efficacy and Safety of Eculizumab in the Treatment of Transplant-Associated Thrombotic Microangiopathy: A Systematic Review and Meta-Analysis

Frontiers in Immunology, 2020
exaly  

Long‐term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria

British Journal of Haematology, 2013
Peter Hillmen, Alexander Röth, Antonio M Risitano   +2 more
exaly  

Different Levels of Incomplete Terminal Pathway Inhibition by Eculizumab and the Clinical Response of PNH Patients

Frontiers in Immunology, 2019
Christof Weinstock, Arne Skerra, Thomas Simmet   +2 more
exaly  

Eculizumab is Efficacious But Often Not Accessible

Journal of Pediatric Hematology/Oncology, 2018
openaire   +2 more sources

Two cases of kidney transplantation‐associated thrombotic microangiopathy successfully treated with eculizumab

Nephrology, 2016
Masayoshi Okumi, Andrew Grey, Khan Muhammad   +2 more
exaly  

Paroxysmal nocturnal haemoglobinuria treatment with eculizumab is associated with a positive direct antiglobulin test

Vox Sanguinis, 2012
Willy A Flegel
exaly  

PNH and eculizumab.

2010
Luzzatto, RISITANO, ANTONIO MARIA, Notaro R.   +2 more
openaire   +1 more source

FDA Report: Eculizumab (Soliris®) for the Treatment of Patients with Paroxysmal Nocturnal Hemoglobinuria

Oncologist, 2008
exaly